Efficacy of the sphingosine-1-phosphate receptor agonist fingolimod in animal models of stroke: an updated meta-analysis

References

• Marshall RS. Progress in intravenous thrombolytic therapy for acute stroke. JAMA Neurol. 2015;72(8):928.
   PubMed Web of Science ®Google Scholar
• Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368(10):893–903.
   PubMed Web of Science ®Google Scholar
• Paul AR, et al. Simultaneous revascularization of the occluded internal carotid artery using the Solitaire as a workhorse wire during acute ischemic stroke intervention. Interv Neuroradiol. 2019:1–6. DOI: 10.1177/1591019919885253. [Epub ahead of print].
   Web of Science ®Google Scholar
• Cheng Z, Geng X, Gao J, et al. Intravenous administration of standard dose tirofiban after mechanical arterial recanalization is safe and relatively effective in acute ischemic stroke. Aging Dis. 2019;10(5):1049–1057.
   PubMed Web of Science ®Google Scholar
• Catanese L, Tarsia J, Fisher M. Acute ischemic stroke therapy overview. Circ Res. 2017;120(3):541–558.
   PubMed Web of Science ®Google Scholar
• Chamorro Á, Meisel A, Planas AM, et al. The immunology of acute stroke. Nat Rev Neurol. 2012;8(7):401–410.
   PubMed Web of Science ®Google Scholar
• Kehrel BE, Fender AC. Resolving thromboinflammation in the brain after ischemic stroke? Circulation. 2016;133(22):2128–2131.
   PubMed Web of Science ®Google Scholar
• Shichita T, Ito M, Morita R, et al. MAFB prevents excess inflammation after ischemic stroke by accelerating clearance of damage signals through MSR1. Nat Med. 2017;23(6):723–732.
   PubMed Web of Science ®Google Scholar
• Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate–modifiers of lymphocyte migration. N Engl J Med. 2006;355(11):1088–1091.
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Suzuki H, Sozen T, et al. Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke. 2010;41(2):368–374.
   PubMed Web of Science ®Google Scholar
• Wacker BK, Park TS, Gidday JM. Hypoxic preconditioning-induced cerebral ischemic tolerance: role of microvascular sphingosine kinase 2. Stroke. 2009;40(10):3342–3348.
   PubMed Web of Science ®Google Scholar
• Ying WM, et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol. 2011;69(1):119–129.
   PubMed Web of Science ®Google Scholar
• Fu Y, Zhang N, Ren L, et al. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci USA. 2014;111(51):18315–18320.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Fu Y, Tian D, et al. Combination of the immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial. Circulation. 2015;132(12):1104–1112.
   PubMed Web of Science ®Google Scholar
• Tian D‐C, Shi K, Zhu Z, et al. Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow. Ann Neurol. 2018;84(5):717–728.
   PubMed Web of Science ®Google Scholar
• Pound P, Ebrahim S, Sandercock P, et al. Where is the evidence that animal research benefits humans? BMJ. 2004;328(7438):514–517.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang C, Tao W, et al. Systematic review and meta-analysis of the efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke. Int J Neurosci. 2013;123(3):163–169.
   PubMed Web of Science ®Google Scholar
• Vesterinen HM, Currie GL, Carter S, et al. Systematic review and stratified meta-analysis of the efficacy of RhoA and Rho kinase inhibitors in animal models of ischaemic stroke. Syst Rev. 2013;2(1):33.
   PubMedGoogle Scholar
• Vesterinen HM, Sena ES, Egan KJ, et al. Meta-analysis of data from animal studies: a practical guide. J Neurosci Methods. 2014;221(15):92–102.
   PubMedGoogle Scholar
• Reaganshaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659.
   PubMed Web of Science ®Google Scholar
• Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol. 2002;13(4):1073–1083.
   PubMed Web of Science ®Google Scholar
• David OJ, Kovarik JM, Schmouder RL. Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet. 2012;51(1):15–28.
   PubMed Web of Science ®Google Scholar
• Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352(9128):609–613.
   PubMed Web of Science ®Google Scholar
• Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40(6):2244–2250.
   PubMed Web of Science ®Google Scholar
• Czech B, Pfeilschifter WON. The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochem Biophys Res Commun. 2009;389(2):251–256.
   PubMed Web of Science ®Google Scholar
• Shichita T, Sugiyama Y, Ooboshi H, et al. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med. 2009;15(8):946–950.
   PubMed Web of Science ®Google Scholar
• Liesz A, Sun L, Zhou W, et al. FTY720 Reduces post-ischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemia. PLos One. 2011;6(6):e21312.
   PubMed Web of Science ®Google Scholar
• Sun W, Zhi-Qiang SU, Song L. Expression of S1P1 in focal brain ischemia-reperfusion rats. J Apoplexy Nerv Dis. 2011;28(2):108–110.
   Google Scholar
• Pfeilschifter W, Czech-Zechmeister B, Sujak M, et al. Treatment with the immunomodulator FTY720 does not promote spontaneous bacterial infections after experimental stroke in mice. Exp Trans Stroke Med. 2011;3(1):2.
   PubMedGoogle Scholar
• Brunkhorst R, Kanaan N, Koch A, et al. FTY720 treatment in the convalescence period improves functional recovery and reduces reactive astrogliosis in photothrombotic stroke. PLoS One. 2013;8(7):e70124.
   PubMed Web of Science ®Google Scholar
• Cai A, et al. Coadministration of FTY720 and rt-PA in an experimental model of large hemispheric stroke–no influence on functional outcome and blood–brain barrier disruption. Exp Transl Stroke Med. 2013;5(1):11.
   PubMedGoogle Scholar
• Campos F, Qin T, Castillo J, et al. Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model. Stroke. 2013;44(2):505–511.
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Suzuki H, Altay O, et al. Role of the sphingosine metabolism pathway on neurons against experimental cerebral ischemia in rats. Transl Stroke Res. 2013;4(5):524–532.
   PubMed Web of Science ®Google Scholar
• Kraft P, Göb E, Schuhmann MK, et al. FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke. 2013;44(11):3202–3210.
   PubMed Web of Science ®Google Scholar
• Xu H, Shah P, Testai FD. 2014 International Stroke Conference and State-of-the-Science of the American Heart Association/American Stroke Association; 2014 FEB 11–14; Embase identification number(PUI) is L71466387.
   Google Scholar
• Nazari M, Keshavarz S, Rafati A, et al. Fingolimod (FTY720) improves hippocampal synaptic plasticity and memory deficit in rats following focal cerebral ischemia. Brain Res Bull. 2016;124:95–102.
   PubMed Web of Science ®Google Scholar
• Schuhmann MK, Krstic M, Kleinschnitz C, et al. Fingolimod (FTY720) reduces cortical infarction and neurological deficits during ischemic stroke through potential maintenance of microvascular patency. Curr Neurovasc Res. 2016;13(4):277–282.
   PubMed Web of Science ®Google Scholar